JANX Janux Therapeutics Inc.

FDA Catalyst Company
10.94
+0.53  (+5%)
Previous Close 10.41
Open 10.77
52 Week Low 9.39
52 Week High 37.99
Market Cap $455,425,275
Shares 41,629,367
Float 15,228,904
Enterprise Value $85,649,799
Volume 18,653
Av. Daily Volume 75,290
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/06/2021
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/06/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/06/2021

Latest News

  1. -IND application recently submitted for PSMA-TRACTr (JANX007)-

    -Company remains on-track to submit IND application for EGFR-TRACTr (JANX008) in 2H 2022-

    -Merck nominates second target as part of strategic collaboration and license agreement-

    -Presented preclinical data for JANX007 and JANX008 at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo-

    -$361.2 million in cash and cash equivalents and short-term investments at end of first quarter 2022-

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr…

    View Full Article
  2. -PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) exhibit enhanced safety and PK properties relative to unmasked TCE-

    -Enhanced PK profile and high exposure of TRACTrs were well tolerated in NHP safety studies with limited healthy tissue toxicities and cytokine release syndrome-

    -Data highlight potential of Janux's TRACTr technology platform to support clinical development-

    -Company remains on-track to submit IND filings for JANX007 in 1H 2022 and JANX008 in 2H 2022-

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today…

    View Full Article
  3. –Company remains on-track to submit IND filings for two programs in 2022–

    –Company nominated its first TRACIr development candidate, a PD-L1 x CD28 costimulatory bispecific–

    –Management team strengthened with key appointment–

    –$375.0 million in year-end 2021 cash, cash equivalents and short-term investments–

    Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

    "Janux made great strides in 2021 as we…

    View Full Article
  4. Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences:

    Cowen's 42nd Annual Health Care Conference
    Forum
    : Panel titled "Novel IO"
    Location: Virtual
    Date: Monday, March 7
    Time: 10:30 a.m. – 11:30 a.m. ET

    Barclays Global Healthcare Conference
    Forum
    : Corporate Presentation
    Location: Miami, Florida
    Date: Wednesday, March 16
    Time: 2:35 p.m. – 3:00 p.m. ET

    Oppenheimer's 32nd Annual Healthcare Conference
    Forum
    : Corporate PresentationLocation:

    View Full Article
  5. Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer. Dr. Robinson brings 30 years of industry expertise and experience from key strategy roles at large pharma companies, including Merck KGaA, Bayer, and Amgen.

    "We are thrilled to welcome Byron to our executive leadership team, bringing his impressive track record of systematically evaluating market opportunities to drive successful clinical strategy," said David Campbell, Ph.D., President…

    View Full Article
View All Janux Therapeutics Inc. News